Clinical Trial Update: A Single Arm, Multicenter, Phase II Trial of RAD001 as Monotherapy in the Palliative Treatment of Patients With TCC After Failure of Chemotherapy [Phase 2]

View source ↗

Summary

A single-arm, multicenter Phase II trial evaluating RAD001 (everolimus) as monotherapy for transitional cell carcinoma after chemotherapy failure has completed.…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Transitional Cell Carcinoma

Drugs mentioned

• RAD001 (everolimus)

Snippet

Sponsor: Cliniques universitaires Saint-Luc- Université Catholique de Louvain | Conditions: Transitional Cell Carcinoma | Phase 2 | Status: COMPLETED